Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 529-536 , December 2009

AML in older patients: Are we making progress?

  • Elihu Estey, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 206 288 7176; Fax: +1 206 288 1119.

References 

  1. Thall P, Estey E. Graphical methods for evaluating covariate effects in the Cox model. In:  Crowley J editors. Handbook of statistics in clinical oncology. New York: Marcel-Dekker; 2001;p. 411–433
  2. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908–1915
  3. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. British Journal of Haematology. 2007;136:624–627
  4. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–1907
  5. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485
  6. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–4187
  7. Erba HP, Kantarjian H, Claxton DF, et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Blood. 2008;112:209;(abstr 558)
  8. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of Clinical Oncology. 2007;25:25–31
  9. Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93:1806–1813
  10. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124
  11. Hills R, O'Brien S, Karsten V, et al. A retrospective comparison of matched elderly patients treated with laromustine (Cloretazine®) or best supportive care or low dose ara-C in the LRF AML14 trial. Blood. 2008;112:1017;(abstr 2960)
  12. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112:1638–1645
  13. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395–1400
  14. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. Journal of Clinical Oncology. 2003;21:1480–1484
  15. Freireich EJ, Gehan EA, Sulman D, et al. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis. 1961;14:593–608
  16. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649
  17. Estey EH, Garcia-Manero G, Giles FJ, et al. Clinical relevance of CRp in untreated AML. Blood. 2005;106:161a;(abstr 541)
  18. Etienne A, Charbonnier A, Prebet T, et al. Impact of CRi on outcome of elderly patients with untreated acute myeloid leukemia (AML). Blood. 2008;112:1030;(abstr 2988)
  19. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood. 2003;102:442–448
  20. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320
  21. Becker H, Marcucci G, Maharry K, et al. NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). J Clin Oncol. 2009;27:356s;(abstr 7000)
  22. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135:165–173
  23. Breems DA, van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791–4797
  24. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87:4979–4989
  25. Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113:28–36
  26. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098
  27. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26:5684–5688
  28. Cashen AF, Schiller GJ, O'Donnell MR, et al. Preliminary results of a multicenter phase II trial of 5-day decitabine as front-line therapy for elderly patients with acute myeloid leukemia (AML). Blood. 2008;112:210;(abstr 560)

PII: S1521-6926(09)00062-0

doi: 10.1016/j.beha.2009.08.007

Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 529-536 , December 2009

Article Tools

* Image Usage & Resolution